

**Appendix 1 (as supplied by the authors):** Medicine–indication pairs

Generic Name	Indication	CADTH CDR	AB	BC	ON	QC
Acidinium bromide	Chronic Obstructive Pulmonary Disease (COPD)	Positive	Positive	Positive	Positive	Positive
Aflibercept	Macular degeneration, age-related	Positive	Unavailable	Unavailable	Positive	Positive
alendronate sodium / cholecalciferol	Osteoporosis	Positive	Positive	Positive	Positive	Unavailable
Alitretinoin	Eczema	Positive	Negative	Positive	Negative	Negative
apixaban	prevention of venous thromboembolic events (VTE)	Positive	Positive	Negative	Positive	Positive
Aripiprazole	Schizophrenia	Positive	Positive	Positive	Positive	Positive
aripiprazole	Schizophrenia and related psychotic disorders	Negative	Positive	Positive	Positive	Positive
Asenapine	Bipolar I disorder	Positive	Positive	Positive	Negative	Negative
Asenapine	Schizophrenia	Negative	Negative	Negative	Negative	Negative
Azelaic acid	Rosacea	Positive	Positive	Positive	Positive	Positive
Azilsartan medoxomil	Hypertension, essential	Negative	Negative	Negative	Negative	Negative
Azilsartan medoxomil + chlorthalidone	Hypertension, essential	Negative	Negative	Negative	Negative	Negative
Aztreonam for inhalation solution	Cystic fibrosis (CF) with chronic pulmonary pseudomonas aeruginosa infections	Positive	Positive	Positive	Positive	Positive
belimumab	Systemic lupus erythematosus	Negative	Negative	Negative	Negative	Negative

**Key**

Positive: positive reimbursement recommendation or listing decision (including any restrictions), Negative: negative reimbursement recommendation or listing decision

AB: Alberta Health, BC: British Columbia PharmaCare, ON: Ontario Public Drug Programs, QC: Institut national d'excellence en santé et en services

Appendix 1 (continued): Medicine–indication pairs

Generic Name	Indication	CADTH CDR	AB	BC	ON	QC
brinzolamide and timolol maleate	Glaucoma and ocular hypertension	Positive	Positive	Positive	Positive	Unavailable
calcitriol	Psoriasis, mild to moderate plaque	Negative	Negative	Negative	Positive	Positive
canakinumab	Cryopyrin-Associated Periodic Syndrome (CAPS)	Negative	Negative	Negative	Positive	Unavailable
certolizumab pegol	Arthritis, rheumatoid	Negative	Positive	Positive	Positive	Positive
clostridium botulinum neurotoxin type A	Blepharospasm	Positive	Positive	Positive	Positive	Positive
clostridium botulinum neurotoxin type A	Cervical Dystonia	Positive	Positive	Positive	Positive	Positive
clostridium botulinum neurotoxin type A	Spasticity, Post-stroke	Negative	Positive	Positive	Negative	Positive
colesevelam hydrochloride	Hypercholesterolemia	Negative	Positive	Positive	Positive	Positive
collagenase clostridium histolyticum	Dupuytren's contracture with a palpable cord	Positive	Negative	Negative	Unavailable	Negative
cyclosporine	Dry eye disease, Moderate to moderately severe	Negative	Negative	Negative	Negative	Negative
dabigatran etexilate	Thromboembolism (venous), prevention	Negative	Positive	Positive	Positive	Negative
denosumab	Osteoporosis, postmenopausal women	Positive	Positive	Positive	Positive	Positive
desvenlafaxine succinate	Depressive, Major Disorder	Negative	Negative	Negative	Negative	Unavailable

**Key**

Positive: positive reimbursement recommendation or listing decision (including any restrictions), Negative: negative reimbursement recommendation or listing decision

AB: Alberta Health, BC: British Columbia PharmaCare, ON: Ontario Public Drug Programs, QC: Institut national d'excellence en santé et en services

Appendix 1 (continued): Medicine–indication pairs

Generic Name	Indication	CADTH CDR	AB	BC	ON	QC
Dexamethasone intravitreal implant	Macular edema following central retinal vein occlusion	Negative	Negative	Negative	Negative	Positive
Dienogest	Pain (pelvic) associated with endometriosis	Positive	Positive	Positive	Positive	Positive
doxycycline monohydrate	Rosacea treatment	Negative	Negative	Negative	Unavailable	Unavailable
dronedarone hydrochloride	Atrial fibrillation	Negative	Unavailable	Positive	Negative	Negative
eculizumab	Paroxysmal nocturnal hemoglobinuria (PNH)	Negative	Positive	Negative	Positive	Negative
eltrombopag olamine	Thrombocytopenic purpura chronic immune (idiopathic)	Negative	Negative	Negative	Positive	Positive
Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate	HIV-1 infection	Positive	Unavailable	Positive	Positive	Positive
emtricitabine / rilpivirine / tenofovir disoproxil fumarate	HIV-1 infection in antiretroviral treatment- naïve adults	Positive	Unavailable	Positive	Positive	Positive
eplerenone	Post myocardial infarction	Negative	Positive	Negative	Positive	Positive
Everolimus	renal angiomyolipoma associated with tuberous sclerosis complex (TSC)	Negative	Negative	Negative	Positive	Positive
Exenatide	Diabetes mellitus, Type 2	Negative	Negative	Negative	Negative	Unavailable
Fampridine	Multiple Sclerosis, improve walking disability	Negative	Negative	Negative	Negative	Negative
febuxostat	Gout	Positive	Positive	Positive	Positive	Positive
Fentanyl citrate	Pain, Cancer (breakthrough	Negative	Negative	Negative	Negative	Negative

**Key**

Positive: positive reimbursement recommendation or listing decision (including any restrictions), Negative: negative reimbursement recommendation or listing decision

AB: Alberta Health, BC: British Columbia PharmaCare, ON: Ontario Public Drug Programs, QC: Institut national d'excellence en santé et en services

Appendix 1 (continued): Medicine–indication pairs

Generic Name	Indication	CADTH CDR	AB	BC	ON	QC
Fesoterodine fumarate	Bladder, overactive	Positive	Positive	Unavailable	Positive	Positive
Fidaxomicin	Clostridium difficile infection	Negative	Positive	Positive	Positive	Positive
Fingolimod	Multiple Sclerosis	Positive	Positive	Positive	Positive	Positive
Fluticasone furoate /vilanterol	Chronic Obstructive Pulmonary Disease (COPD)	Positive	Positive	Positive	Positive	Positive
Glycopyrronium bromide	Chronic Obstructive Pulmonary Disease (COPD), maintenance bronchodilator treatment	Positive	Positive	Positive	Positive	Positive
golimumab	Arthritis, Rheumatoid	Positive	Positive	Positive	Positive	Positive
golimumab	Arthritis, psoriatic	Positive	Positive	Positive	Positive	Positive
golimumab	Ankylosing spondylitis	Positive	Positive	Positive	Positive	Positive
Grass Pollen Allergen Extract	Allergic rhinitis (grass pollen)	Positive	Unavailable	Negative	Positive	Positive
Guanfacine hydrochloride	Attention-deficit/hyperactivity disorder (ADHD)	Negative	Negative	Negative	Unavailable	Positive
hydromorphone hydrochloride	Pain, Chronic (moderate to severe)	Negative	Unavailable	Positive	Negative	Negative
Indacaterol	Chronic Obstructive Pulmonary Disease (COPD), maintenance bronchodilator treatment	Positive	Positive	Positive	Positive	Positive
Indacaterol/glycopyrronium	COPD	Positive	Positive	Positive	Positive	Positive
Ingenol mebutate	Keratosi s, actinic	Negative	Negative	Negative	Negative	Negative
Insulin glulisine	Diabetes, Mellitus (Type 1 & 2)	Positive	Positive	Positive	Positive	Positive

**Key**

Positive: positive reimbursement recommendation or listing decision (including any restrictions), Negative: negative reimbursement recommendation or listing decision

AB: Alberta Health, BC: British Columbia PharmaCare, ON: Ontario Public Drug Programs, QC: Institut national d'excellence en santé et en services

Appendix 1 (continued): Medicine–indication pairs

Generic Name	Indication	CADTH CDR	AB	BC	ON	QC
Interferon beta Positivea	Clinically Isolated Syndrome	Negative	Positive	Negative	Positive	Positive
lacosamide	Epilepsy, partial onset seizures	Positive	Positive	Positive	Positive	Positive
Levodopa / carbidopa	Parkinson's disease	Negative	Negative	Negative	Negative	Negative
Linagliptin	Diabetes mellitus, Type 2	Positive	Positive	Positive	Positive	Positive
Linagliptin-metformin	Diabetes mellitus (Type 2)	Positive	Positive	Positive	Positive	Positive
liraglutide	Diabetes mellitus, Type 2, dual therapy	Negative	Negative	Negative	Negative	Positive
Lisdexamfetamine dimesylate	Attention deficit hyperactivity disorder	Negative	Positive	Negative	Negative	Positive
loteprednol etabonate	Post-operative inflammation following cataract surgery	Negative	Unavailable	Negative	Unavailable	Negative
lurasidone	schizophrenia	Positive	Positive	Negative	Positive	Positive
Methylnaltrexone bromide	Constipation, Opioid-induced	Negative	Negative	Negative	Negative	Negative
Mirabegron	Bladder, overactive	Positive	Positive	Unavailable	Positive	Positive
Mometasone furoate	Asthma, (Bronchial) Prophylactic management of steroid responsive	Positive	Positive	Positive	Positive	Positive
Mometasone furoate and formoterol	Asthma maintenance (adults, children 12 or older)	Negative	Negative	Positive	Positive	Negative
Nebivolol	hypertension essential	Negative	Unavailable	Negative	Negative	Negative
olmesartan medoxomil	Hypertension	Positive	Positive	Positive	Positive	Positive
olmesartan medoxomil + hydrochlorothiazide	Hypertension	Positive	Positive	Positive	Positive	Positive

**Key**

Positive: positive reimbursement recommendation or listing decision (including any restrictions), Negative: negative reimbursement recommendation or listing decision

AB: Alberta Health, BC: British Columbia PharmaCare, ON: Ontario Public Drug Programs, QC: Institut national d'excellence en santé et en services

Appendix to: Allen N, Walker SR, Liberti L, et al. Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study. *CMAJ Open* 2016. DOI:10.9778/cmajo.20160006. Copyright © 2016 Joule Inc. or its licensors

Appendix 1 (continued): Medicine–indication pairs

Generic Name	Indication	CADTH CDR	AB	BC	ON	QC
OnabotulinumtoxinA	Neurogenic Detrusor Overactivity	Positive	Positive	Positive	Positive	Positive
Oxybutynin Chloride Gel	Bladder, overactive	Negative	Negative	Negative	Negative	Negative
Paliperidone palmitate	Schizophrenia	Negative	Positive	Positive	Positive	Positive
Palonosetron hydrochloride	Nausea and vomiting (chemotherapy induced) prevention	Negative	Negative	Negative	Negative	Negative
Palonosetron hydrochloride	Nausea and vomiting (chemotherapy induced) prevention	Negative	Negative	Negative	Unavailable	Negative
Pirfenidone	Pulmonary fibrosis (idiopathic, mild to moderate)	Negative	Negative	Negative	Positive	Negative
Plerixafor	Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma	Negative	Positive	Negative	Positive	Positive
Prasugrel hydrochloride	Acute Coronary Syndrome (ACS)	Negative	Negative	Positive	Negative	Positive
prucalopride	Constipation, chronic	Negative	Negative	Negative	Negative	Unavailable
Ranibizumab injection	Macular edema, secondary to retinal vein occlusion, (branch retinal vein occlusion)	Positive	Negative	Unavailable	Positive	Positive
Remicade	Ulcerative Colitis	Negative	Positive	Negative	Positive	Positive
rilpivirine	HIV (treatment - naive adult)	Positive	Unavailable	Positive	Positive	Positive
Riociguat	Pulmonary hypertension, chronic thromboembolic	Positive	Negative	Negative	Positive	Positive
Rivaroxaban	Thromboembolic events (venous), pulmonary embolism	Positive	Positive	Positive	Positive	Positive

**Key**

Positive: positive reimbursement recommendation or listing decision (including any restrictions), Negative: negative reimbursement recommendation or listing decision

AB: Alberta Health, BC: British Columbia PharmaCare, ON: Ontario Public Drug Programs, QC: Institut national d'excellence en santé et en services

Appendix 1 (continued): Medicine–indication pairs

Generic Name	Indication	CADTH CDR	AB	BC	ON	QC
roflumilast	Chronic obstructive pulmonary disease (COPD)	Negative	Negative	Negative	Negative	Negative
romiplostim	Chronic immune (idiopathic) thrombocytopenic purpura (ITP)	Negative	Unavailable	Negative	Negative	Negative
Rotigotine	Parkinson's Disease	Positive	Negative	Negative	Negative	Negative
Rufinamide	Lennox-Gastaut syndrome; adjunctive treatment of seizures	Positive	Negative	Positive	Positive	Positive
sapropterin dihydrochloride	Phenylketonuria (PKU).	Negative	Negative	Negative	Negative	Positive
saxagliptin	Diabetes mellitus (Type 2)	Positive	Positive	Positive	Positive	Positive
Saxagliptin + metformin	Diabetes Mellitus, Type 2	Positive	Unavailable	Positive	Positive	Positive
Silodosin	Prostatic Hyperplasia, benign	Negative	Negative	Negative	Positive	Positive
sitagliptin phosphate monohydrate / metformin hydrochloride	Diabetes mellitus (Type 2)	Positive	Positive	Positive	Positive	Positive
Sofosbuvir	Hepatitis C, chronic	Positive	Positive	Positive	Positive	Positive
Somatropin	Growth hormone deficiency, adult	Positive	Positive	Negative	Positive	Positive
Somatropin	Growth hormone deficiency, pediatric	Positive	Unavailable	Positive	Positive	Positive
Somatropin	Turner Syndrome	Positive	Unavailable	Negative	Positive	Unavailable
Stiripentol	Dravet Syndrome	Positive	Positive	Positive	Positive	Positive
tadalafil	Pulmonary arterial hypertension	Positive	Unavailable	Positive	Positive	Positive
tapentadol	Pain, moderate to moderately severe	Negative	Negative	Negative	Negative	Negative

**Key**

Positive: positive reimbursement recommendation or listing decision (including any restrictions), Negative: negative reimbursement recommendation or listing decision

AB: Alberta Health, BC: British Columbia PharmaCare, ON: Ontario Public Drug Programs, QC: Institut national d'excellence en santé et en services

Appendix 1 (continued): Medicine–indication pairs

Generic Name	Indication	CADTH CDR	AB	BC	ON	QC
Telaprevir	Hepatitis C infection (genotype 1), Chronic (treatment experienced)	Positive	Unavailable	Positive	Negative	Positive
Telmisartan / Amlodipine	Hypertension, Essential	Positive	Positive	Positive	Positive	Positive
Ticagrelor	Thrombotic events in Acute Coronary Syndromes, Prevention	Negative	Positive	Positive	Negative	Positive
tocilizumab	Arthritis, Rheumatoid	Positive	Positive	Positive	Positive	Positive
tolvaptan	Hyponatremia, non-hypovolemic	Negative	Negative	Negative	Unavailable	Negative
Ustekinumab	Psoriasis	Positive	Positive	Positive	Positive	Positive
velaglucerase alfa	Gaucher Disease	Positive	Positive	Positive	Positive	Negative
Zolpidem tartrate	Insomnia, short-term treatment	Negative	Negative	Negative	Negative	Negative

**Key**

Positive: positive reimbursement recommendation or listing decision (including any restrictions), Negative: negative reimbursement recommendation or listing decision

AB: Alberta Health, BC: British Columbia PharmaCare, ON: Ontario Public Drug Programs, QC: Institut national d'excellence en santé et en services